Oncotelic Therapeutics, Inc.

OTLC

US6283411097

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 19:27:22 03/06/2024 BST			5-day change	1st Jan Change
0.0376 ^USD	+1.21%		+1.62%	-1.83%

05-15	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mateon Therapeutics, Inc. Announces Resignation of Dr. Fatih Uckun as Chief Medical Officer

January 06, 2020 at 08:54 pm

Mateon Therapeutics, Inc. announced resignation of Dr. Fatih Uckun as Chief Medical Officer, effective January 6, 2020.

Latest news about Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	03-25	CI
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	11-15	MT
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Oncotelic Therapeutics, Inc. announces tranche update	23/10/23	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
Oncotelic Launches PDAO SEC chatbot	24/04/23	CI
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology	19/04/23	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23	CI
Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	13/04/23	CI
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem	13/03/23	CI
Oncotelic Therapeutics, Inc. announced that it expects to receive $5 million in funding	09/03/23	CI
Oncotelic Therapeutics, Inc. Announces Executive Changes	02/03/23	CI
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer	06/02/23	CI
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer	25/01/23	CI
Oncotelic Therapeutics, Inc. Announces Launch of Wholly Owned Subsidiary, Pet2DAO Inc. and its Associated Token PDAO	17/01/23	CI
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022	19/12/22	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas	08/11/22	CI
Oncotelic Therapeutics, Inc. cancelled the transaction announced on October 25, 2021	24/10/22	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22/08/22	CI
Oncotelic Therapeutics, Inc. announced that it has received $0.3015 million in funding from BlueLake Partners, LLC	21/06/22	CI
Oncotelic Therapeutics, Inc. announced that it has received $0.5445 million in funding from Mast Hill Management, LLC	26/05/22	CI

Chart Oncotelic Therapeutics, Inc.

Duration

Period

More charts

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâs Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-Î²2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOTELIC THERAPEUTICS, INC.	-1.83%	15.26M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	121B
REGENERON PHARMACEUTICALS, INC.	+12.66%	107B
BIONTECH SE	-2.53%	24.82B
ARGENX SE	+1.16%	22.48B
GENMAB A/S	-9.35%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-18.92%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	14.08B
SAREPTA THERAPEUTICS, INC.	+28.83%	11.74B

Bio Therapeutic Drugs

Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Biotechnology & Medical Research

Mateon Therapeutics, Inc. Announces Resignation of Dr. Fatih Uckun as Chief Medical Officer

Latest news about Oncotelic Therapeutics, Inc.

Chart Oncotelic Therapeutics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs